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BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. 
MicroRNA (miRNA)-21 showed its stability in circulation 
and could serve as powerful biomarker. The aim of this 
study was to evaluate miRNA-21 as breast cancer biomarker 
compared to CA 15-3 in Indonesian population. 
METHODS: Circulating  plasma miRNA-21 expression 
was measured using qRT-PCR in 49 patients at various 
stages of breast cancer and 16 healthy controls. The 
relative expression value of miRNA-21 was calculated 
using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using 
electrochemiluminescence immunoassay (ECLIA) 
methods. The results of miRNA-21 and CA 15-3 plasma 
circulating expression were compared with controls at each 
stage and between stages of breast cancer.
RESULTS: CA 15-3 median level in breast cancer group 
was 1.60 times higher compared to control group (p=0.019), 
21.00 m/mL and 13.05 m/mL, respectively. Median 
miRNA-21 expression in breast cancer group was elevated 
4.92 folds compared to control group (p=0.001), 4.43 and 
0.90, respectively. There was no significant difference of CA 
15-3 level between controls and all stages of breast cancer 
group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) 
with 59.2% sensitivity and 62.5% specificity. Meanwhile, 
there was a significant difference of miRNA-21 expression 
between controls and most stages of breast cancer group. 
Circulating miRNA-21 expression cut-off value was 2.07 
(p=0.000) with 91.8% sensitivity and 87.5% specificity. 
CONCLUSION: Circulating miRNA-21 expression 
and CA 15-3 levels were significantly increased in breast 
cancer group compared to control group. The miRNA-21 
expression increased consistently with breast cancer stage 
progression. miRNA-21 could serve as superior biomarker 
compared to CA 15-3.
KEYWORDS: biomarker, breast cancer, circulating 
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Abstract
Introduction
World-widely, breast cancer is well known as the most 
prevalent malignancy in women, in line with its morbidity 
and mortality.(1) The high prevalence of breast cancer 
used to be dominated by the western countries. However, 
nowadays breast cancer incidence trends shifts towards 
developing countries and Asian population, including 
Indonesia.(2)
 The management of breast cancer requires a 
comprehensive approach, consisting diagnostic, therapeutic 
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and monitoring procedures to ensure  better outcome in 
mortality and morbidity.(3) Being an initial stage in the 
management of breast cancer, the diagnostic procedure is a 
critical point, along with its prognosis.(3)
 The present standardized triple test approach for 
breast cancer, which includes clinical, radiological and 
histopathological  examinations,  is  well  known  for  its 
decent  specificity  and  sensitivity.  However,  there  are 
several issues lies in this approach.(4,5) Meanwhile, 
mammography has shown a limitation in young women 
with a dense breast tissue.(6) Invasiveness of breast biopsy 
is also considered to be inconvenient for some patients.(7) 
 Non-invasive and minimal-invasive methods of 
diagnostic are also proved to be preferable modalities 
compared to an invasive procedure. There are several 
established tumor marker that are well known in routine 
practice, including carcino-embryonic antigen (CEA), 
carbohydrate antigens 15-3 (CA 15-3), and carbohydrate 
antigens 27-29 (CA 27-29).(8) Yet, these biomarkers show 
relatively poor sensitivity and specificity.(9) The issues of CA 
15-3 detection especially caused by an increase of CA 15-3 
levels in several particular diseases, including liver cirrhosis 
and other adenocarcinoma, which hinders its specificity.
(10,11) In the recent development, circulating breast cancer 
biomarker research is still performed worldwide in a quest 
to pinpoint the particular biomarker molecules. 
 miRNA is present in the circulation and known to be 
an important regulator molecules in cells metabolism and 
oncogenesis.(12) Moreover, miRNA also showed relatively 
stable nature. Existence of several constantly endogeneous 
expressed  miRNA  that  can  be  utilized  as  a  miRNA 
baseline might  strengthen  its  potential  as  a  biomarker  in 
malignancy.(13) In breast cancer there are several miRNA 
that have proved to correlate with disease progression, 
either in line or inversely. The search continues to find 
the most suitable miRNA, which correlates with breast 
cancer progression.(3,12) miRNA-21, miRNA-29b, and 
miRNA-155 have been shown to have an in line correlation 
to  breast  cancer  progression.(14)  However  miRNA-21 
shows relatively favorable correlation compared to other 
miRNAs.(14) 
 miRNA-21 is known as a regulator of several identified 
target genes, including tumor suppressor tropomyosin 
1 (TPM1), network of p53, PDCD4, PTEN, and Maspin.
(13) miRNA-21 interacts with these genes and regulated 
cells proliferation, oncogenesis, and cell migration.(15) 
Supported by the previous studies, miRNA-21 was also 
used for evaluation of breast cancer progression, prognosis, 
and survival.(16) Previous study also showed a correlation 
between circulating level of miRNA-21, circulating  tumor 
cells  and  tissue  level  of  miRNA-21 which  indicated 
that measurement of circulating miRNA-21 level could 
potentially represent breast cancer progression.(14,17) 
Therefore, based on these data the investigation of 
miRNA-21 as a breast cancer biomarker for the disease’s 
progressivity monitoring and diagnostic should be 
performed especially in Indonesia. The importancy of 
assessing miRNA level in healthy population is also needed, 
as the miRNA-21 evaluation in Indonesian population was 
never been assessed before. This data could suggest whether 
miRNA expression could serve as a breast cancer biomarker 
in Indonesian population.
Methods
Subject Selection
In this study, serum samples from 65 women above 18 years 
old were analyzed. Among them were 49 patients with 
breast cancer and 16 healthy women as control. Samples 
were taken from newly diagnosed breast cancer (stage 
1–4) patients recruited from the Hematology and Medical 
Oncology Outpatient Clinic of Universitas Airlangga 
Hospital, Surabaya, before undergoing chemotherapy 
and radiotherapy. Breast cancer diagnosis was confirmed 
by physical examination, radiological examination, and 
histopathological examination. The samples of healthy 
control were obtained from age-matched women, who 
had no history of malignancy or comorbid disease such as 
chronic hepatitis, liver cirrhosis and has been proven to be 
healthy by physical examination. 
 Written informed consent from all patients was 
obtained for blood collection at the unit of clinical 
laboratory of Universitas Airlangga Hospital. This process 
was approved by Bioethical Committee of Universitas 
Airlangga Hospital (Ethical Clearance Document Registry 
Number 164/KEP/2019). The entire subject characteristics 
data were collected from patient medical record. Menarche 
status and other data that were not obtained in medical 
record was obtained from anamnesis. 
 Blood sample collection was performed to the 
entire subjects after receiving written informed consent 
in Hematology-Medical Oncology policlinic, Universitas 
Airlangga Hospital, The 10 ml peripheral blood was 
collected through venipuncture. The blood then stored in 
ethylenediaminetetraacetic acid (EDTA) vacuum container 
and divided into two tubes for both CA 15-3 and miRNA-21 
examination.
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CA 15-3 Examination
Plasma from peripheral venous blood was obtained after 
collection to EDTA containing vacuum container and 
incubation for 1 hour in room temperature. Before plasma 
was collected the tube were centrifuged 5 minutes in 1900G 
to  ensure  purity  of  plasma.  A  total  of  20  μL  of 
subject plasma was diluted to 1:10 with Diluent Universal. 
After dilution the streptavidin-coated microparticle was 
added for sticking it to solid phase, forming a reaction 
mixture. Reaction mixture was transferred to measuring 
cell where the microparticles are captured by magnetic 
electrode, unbound substances then removed by washing 
with ProCell/ProCell M (Roche Diagnostics GmbH, 
Mannheim, Germany). Electrical current then applied to 
electrode that will producing a electroluminescent signal 
which will be captured by photomultiplier. Determination 
of electrochemiluminescent signal was performed by 
based on calibration curve from 2-point calibration and 
master curve, which present with each reagent barcode. 
The level of CA 15-3 was obtained from an automatic 
process of quantification through COBAS ECLIA analyzer 
(Roche Diagnostics, Basel, Switzerland). This procedure 
was performed according to Elecsys CA 15-3 II ECLIA 
kit. Normal reference limit that used was ≤25 m/mL. CA 
15-3 examination was performed in the Prodia Clinical 
Laboratory, Surabaya and Jakarta.
Blood Sample Preparation
Plasma separation was performed by centrifuging EDTA 
venous blood sample from EDTA vacuum container after 1 
hour storage at room temperature using a swinging bucket 
rotor for 10 minutes at 1900G and 4°C. Plasma from the 
sample was collected without disturbing buffy coat layer. 
Collected plasma then transferred to conical tubes and 
recentrifuged for 10 minutes at 16000 g and 4°C in a fixed-
angle rotor. Clear plasma supernatant was collected without 
disturbing the pellet.
RNA Extraction and Reverse Transcription
Total RNA extraction was performed following 
manufacturer’s instruction of the Qiagen miRNeasy Serum/
Plasma Kit (Cat. No. 217184, Qiagen, Hilden, Germany). 
The quantification of total RNA was performed using 
NanoDrop™ (Thermo Scientific, Massachuset, USA).
 Total isolated RNA from plasma then was transferred 
and underwent reverse transcription for producing cDNA 
that needed for qRT-PCR analysis. Reverse transcription 
was carried out using TaqMan MicroRNA Reverse 
Transcription kit (Cat. No. 4366596,  Applied Biosystems, 
Carlsbad, California, USA) by mixing 3μL of RT primer 
and 5μL RNA sample (contains 1-10ng RNA) with 7μL of 
reverse transcription reaction mix. Thermal cycle setting 
that used was 16°C for 30 minutes, 42°C for 30 minutes, 
85°C for 5 minutes and 4°C for holding reaction. The primer 
that was utilized are Hsa-miR-21-3p (miRNA-21) and Hsa-
miR-16-5p (miRNA-16) as endogenous control.
Quantitative Real-Time Polymerase Chain Reaction 
(qRT-PCR)
qRT-PCR from cDNA was performed using TaqMan_
MicroRNA assay (Applied Biosystems), TaqMan 
endogenous control assay for miRNA-16 (Applied 
Biosystems), and Taqman_ Universal PCR master mix II, 
No UNG (Applied Biosystems) by transferring and mixed 
previous cDNA with PCR Reaction mix. The thermal cycle 
setting for qRT-PCR was 95°C for 10 minutes (1 cycle), 
95°C for 15 seconds, and 60°C  for 60 seconds (40 cycles).
Data Analysis
The data that was acquired which encompass patient 
characteristics, CA-15-3 level, and circulating 
miRNA-21 expression. The data analysis were carried 
out by performing homogeneity test for age-matching and 
menarche status-matching using Chi-square test, normality 
distribution analysis (Levene’s Test) and non-parametric 
statistic analysis by using IBM SPSS Statistics v.24.0 (IBM 
Corporation, New York, USA).
Results
Demographic Characteristics
Age matching analysis was performed to represent the 
healthy control groups as a comparison to breast cancer 
subjects groups for minimizing the relative risk of breast 
cancer based on the age variables. Menarche status between 
healthy control subjects and breast cancer subjects group 
also has been matched for minimizing the breast cancer 
hormonal relative risk difference in pre-menopause and 
menopause subjects. In the breast cancer group (n=49), 
the research subjects with stage 1 (n=5) breast cancer were 
10.2%, stage 2 was 42.85% (n=21), stage 3 was 20.40% 
(n=10) subjects, and stage 4 in this study was found in 
26.53% (n=13) subjects (Table. 1)
Circulating miRNA-21 Level Expression 
The circulating miRNA-21 level expression was different in 
breast cancer and healthy control subjects. The expression 
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Breast Cancer Subjects
(n=49)
Healthy Control Subjects
(n=16)
Age (years), mean±SD 51.95±10.21 49.75±10.42 0.925
Menarche status 0.940
     Pre-menopause 25 (51.02) 9 (56.25)
     Menopause 24 (48.97) 7 (43.75)
Tumor staging
Stage 1 5 (10.20)
Stage 2 21 (42.85)
Stage 3 10 (20.40)
Stage 4 13 (26.53)
Variable
n (%)
p- value
Table 1. Demographic characteristic.
Age matching and menarche status matching in the breast cancer groups and healthy subjects group 
(Mann-Whitney test) with breast cancer patient cancer staging.
of miRNA-21 in the breast cancer group as a whole was 
4.92 times higher than the expression of miRNA-21 in 
the control group. A significant difference was obtained in 
the comparison of the expression of circulating miRNA-2 
breast cancer groups at among stage I, II, III, IV breast 
cancer patient, and control group (p=0.001) (Table 2).
Circulating miRNA-21 Expression Level and CA 15-3 
Level Sensitivity and Specificity
The cut-off value of CA 15-3 was obtained in the breast 
cancer group of 15.05 with an area under the ROC curve 
(ROC-AUC) of 0.701 (70.1%, with p=0.016) and sensitivity 
of 59.2% and specificity by 62.5%. 
 On the other hand, the expression of circulating 
miRNA-21 in the breast cancer group, showed a cut-off 
value of 2.07 with an area under the ROC curve (ROC-
AUC) of 0.931 (93.1%, with p=0.000), and a sensitivity of 
91.8% and specificity of 87.5% (Figure 1).
CA 15-3 Level Expression 
In  this  study,  CA 15-3  levels  in the  breast  cancer  group 
were 1.60 times higher compared to CA 15-3 levels in 
the control group. The results obtained were significant 
differences in the comparison of CA levels of 15-3 breast 
cancer groups at among stage 1, 2, 3, 4, and control groups 
(p=0.019) (Table 3). 
Median (Min-Max) Mean±SD Median Fold Change
Healthy control subjects (n=16) 0.90 (0.16-4.53) 1.35±1.18 4.92 0.001
Breast cancer subjects (n=49) 4.43 (1.11-32.22) 6.00±5.35
     Stage 1  (n=5) 4.75 (2.88-5.35) 4.31±0.97
     Stage 2  (n=21) 3.68 (1.18-11.79) 4.62±3.13
     Stage 3  (n=10) 3.83 (1.11-14.12) 5.40±4.27
     Stage 4 (n=13) 5.77 (3.18-32.22) 9.32±8.21
Early stage breast cancer (Stage 1 & 2) 3.93 (1.18-11.79)
Advanced stage breast cancer (Stage 3 & 4) 5.09 (1.11-32.22)
Variable
Circulating miRNA-21 Expression (2-ΔΔCt)
p-value
Table 2. Circulating miRNA-21 level expression comparison in different stage of breast cancer and healthy control 
subjects.
miRNA-21 expression in the breast cancer group was significantly different compared to healthy groups with 4.92 fold median 
changes (Mann-Whitney test). miRNA-21 expression also could distinguish early stage and advanced stage breast cancer.
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miRNA-21
CA 15-3
Reference Line
Se
ns
iti
vi
ty
1.0
0.8
0.6
0.4
0.2
0 0.2             0.4            0.6            0.8            1.0
Variable                                  Sensitivity                      Specificity
CA 15-3                                               59.2%                              62.5%
miRNA-21 (2       )                              91.8%                              87.5%-∆∆Ct
Figure 1. ROC curve of CA 15-3 and miRNA-21 
in distinguishing between breast cancer and 
healthy subjects.
Median (Min-Max) Mean±SD Median Fold Change
Healthy control subjects (n=16) 13.05 (5.2-19.9) 12.65±5.13 1.6 0.019
Breast cancer subjects (n=49) 21.00 (4.73-3000) 128.27±441.74
     Stage 1  (n=5) 9.80  (4.73-27.8) 12.24±9.25
     Stage 2  (n=21) 12.40  (6.30-57.2) 18.48±13.83
     Stage 3  (n=10) 28.30 (8.94-130.20) 37.06±34.68
     Stage 4 (n=13) 98.50 (5.00-3000) 420.40±808.21
Variable
CA 15-3 (µ/mL)
p- value
CA 15-3 level in the breast cancer group was significantly different compared to healthy groups with 1.6 fold median 
changes (Mann-Whitney test).
Table 3. CA 15-3 level expression comparison in different stage of breast cancer and  healthy control subjects.
Comparison of Circulating miRNA-21 Level and CA 
15-3 Level
In this study, CA levels 15-3 had no meaningful results in 
the comparison between controls with all stages of breast 
cancer and the comparison between stages in the breast 
cancer group. The miRNA-21 level in control group was 
significantly different compared to subjects in breast 
cancer group with stage 1, 2, and 4. However, there was 
no significant difference between control group and subject 
with stage 3 breast cancer (Table 4, Figure 2).
Discussion
This study was performed for assessing the clinical utility 
of circulating miRNA-21 expression measurement in 
patients with  breast  cancer  in  comparison  to CA 15-3 
as a conventional breast cancer marker.(12,18,19) In this 
research, venous blood plasma sample as source material 
for circulating plasma miRNA-21 expression measurement 
was chosen due to its advantage over serum materials. 
Occurrence of hemolysis is more minimal during plasma 
collection compared to serum which minimized confounding 
factors for miRNA-21 expression analysis.(20) 
 CA 15-3, a form of surface-soluble protein-linked 
Mucin 1 (MUC-1), including the Mucin family. It is also 
known as MUC-1 and is involved in cell protection and 
lubrication. Mucin 1 is a high molecular weight (300 KDa) 
glycoprotein. CA 15-3 is expressed in the apical aspects 
of the glandular epithelium and breast cell ducts. CA 15-3 
measurement is useful as a marker for detecting recurrence 
and monitoring the treatment of metastatic breast cancer.(4) 
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Table 4. Comparison of miRNA-21 and CA 15-3 in 
distinguishing different stage of breast cancer and control.
CA 15-3 miRNA-21
Control/Stage 1 1.000 0.003
Control/Stage 2 0.407 0.001
Control/Stage 3 0.256 0.089
Control/Stage 4 0.407 0.03
Stage 1/Stage 2 0.743 0.995
Stage 1/Stage 3 0.278 0.936
Stage 1/Stage 4 0.406 0.255
Stage 2/Stage 3 0.51 0.984
Stage 2/Stage 4 0.42 0.325
Stage 3/ Stage 4 0.465 0.587
Stage
p -value
Control Group              Breast Cancer Group                            Control Group               Breast Cancer Group
CA 15-3 Level miRNA-21 Expression
60
50
40
30
20
10
0
35
30
25
20
15
10
5
0
Figure 2. Comparison of CA 15-3 level and miRNA-21 expression in breast cancer and healthy control subjects. Black bar indicated 
median of CA 15-3 and miRNA-21 expression, white bullet indicated each sample data. Note: There were 8 outliers data ranging >60 (98.5; 
130.2; 130.7; 428.3; 507; 564.1; 587.9; 3000) that excluded in the graphic of CA 15-3 level.
Unfortunalety, CA 15-3 sensitivity and specificity are low 
at 22.4% and 15.7% respectively for detecting early breast 
cancer.(9) The CA15-3 measurement series are currently not 
recommended by American Society of Clinical Oncology 
(ASCO), European Society for Medical Oncology (ESMO), 
and National Comprehensive Cancer Network (NCCN) 
expert panel. However, this biomarker still exhibits 
moderate prognostic value in monitoring advanced stages 
of breast cancer, especially those related to metastasis. 
CA 15-3 is more reliable in the context of advanced breast 
cancer in the management of patient responses to systemic 
therapy.(21,22)
 MiRNA-21 is an intron miRNA (the pri-miR-21 
coding gene is in the intron region). The gene that codes 
for pri-miRNA-21 is on chromosome 17q23.2, overlapping 
with the gene that codes for the TMEM49 protein (VMP-
1).(23) MiRNA-21 plays a role in the process of cell 
proliferation, migration, invasion, preventing apoptosis of 
cancer cells.(15) The target gene is the tumor suppressor 
gene group. The miRNA-21 targets that have been identified 
are tropomyosin 1 tumor suppressor (TPM1), Signaling 
network of p53, PDCD4 and Maspin26.(24-26) MiRNA-21 
can trigger the proliferation and transformation of breast 
cells through suppressing the translation of PDCD4 tumor 
suppressor protein, so that the role of PDCD4 in controlling 
neoplasm cell proliferation and transformation is decreased.
(27) Due to the effect of miRNA-21 on its target, miRNA-21 
can regulate cell proliferation, neoplastic transformation, 
and cell migration.(13)
 Our research revealed that the miRNA-21 serum 
expression and CA 15-3 was found to be increased in breast 
cancer patients compared to healthy controls, however 
miRNA-21 showed a more vivid distinction with its 
specificity and sensitivity. These results were in agreement 
with the findings of previous study, which reported an 
increase in miRNA-21 in breast cancer patients compared 
with healthy group while CA 15-3 was elevated in patients 
with metastasis.(28)  
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 In healthy people, miRNA-21 is expressed lower 
than in the breast cancer group because there are no risk 
factors for breast cancer such as age, family history of 
cancer, hormonal (menarche status, estrogen hormone), 
diet, carcinogenic substances, genetic mutations do not 
arise and DNA damage on chromosome 17q23.1 location of 
miRNA-21 gene, so that biogenesis of miRNA-21 is running 
properly, and there is no over-expression of miRNA-21 that 
affects the process of cell growth, cell proliferation and 
differentiation and cell apoptosis.(29) We observed the low 
level of miRNA-21 in the healthy subjects in line with the 
literature study with a noticeable increase until reaching 
4.92 folds increase in breast cancer subjects. The results of 
this study were inline with previous study, which reported 
4.4 folds increase of miRNA-21 expression.(28) miRNA-21 
expression levels might be able to differentiate early stage 
(stage 1 and 2) and advance stage breast cancer (stage 3 
and 4). Similarly, previous study also reported increasing 
miRNA-21 expression in breast cancer along with the stage 
progression.(30,31) 
 The cut-off value of CA 15-3 that was obtained in the 
breast cancer group was 15.05 with an area under the ROC 
curve (ROC-AUC) of 0.701 (70.1%, with p=0.016) and 
sensitivity of 59.2% and specificity by 62.5%. Meanwhile, 
the expression of circulating miRNA-21 in the breast cancer 
group exhibit 2.07 cut-off value with an area under the ROC 
curve (ROC-AUC) of 0.931 (93.1%, with p=0.000), and 
91.8% sensitivity and 87.5% specificity. Although between 
CA 15-3 levels and miRNA-21 circulating expression 
obtained significant results, miRNA-21 has a wider and 
more meaningful AUC than CA 15-3. Moreover, the 
sensitivity and specificity of miRNA-21 are also higher than 
CA 15-3. 
 The results of this study are consistent with the 
previous studies which suggesting that the detection of 
circulating miRNA-21 level could serve as a novel superior 
biomarker for breast cancer, compared to CA 15-39,14,28. 
Therefore, the application of miRNA-21 as a breast cancer 
biomarker in the recent development could potentially 
provide clinician with better breast cancer biomarkers and 
ensuring better patients quality of live and management 
quality.
Conclusion
Although both CA 15-3 levels and miRNA-21 circulating 
expression showed a significant result between breast 
cancer group and control group, miRNA-21 expression 
increased consistently with breast cancer stage progression. 
miRNA-21 exhibit higher specificity and sensitivity with 
lower cut-off value. Therefore, miRNA-21 is superior 
breast cancer biomarker for Indonesian population. Yet, 
a multicenter study for evaluation of epigenetics factors 
which may affects miRNA-21 expression in Indonesia is 
still needed. Moreover, miRNA-21 may fill the gap that CA 
15-3 still lacks in detecting breast cancer stage progression.
References
1.  Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 
Global cancer statistics 2018: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer 
J Clin. 2018; 68: 394-424. 
2.  Forman D, Ferlay J, Steward BW, Wild CP. The global and regional 
burden of cancer. In: Stewart BW, Wild CP, editors. World Cancer 
Report 2014. Geneva: WHO Press; 2014. 
3.  Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for 
early breast cancer diagnosis, prognosis and therapy prediction. 
Pharmacol Ther. 2017; 172: 34-49. 
4.  Sandya Rani GSB, Bitla A. Breast cancer diagnosis – role of 
biomarkers. J Clin Sci Res. 2017; 6: 225-36.
5.  Kharkwal S, Sameer A, Mukherjee A. Triple test in carcinoma breast. 
J Clin Diagnostic Res. 2014; 8: NC09-NC11. 
6.  Kahraman M, Röske A, Laufer T, Fehlmann T, Backes C, Kern F, et 
al. MicroRNA in diagnosis and therapy monitoring of early-stage 
triple-negative breast cancer. Sci Rep. 2018; 8: 11584. doi: 10.1038/
s41598-018-29917-2.
7.  Heywang-Köbrunner SH, Hacker A, Sedlacek S. Advantages and 
disadvantages of mammography screening. Breast Care. 2011; 6: 
199-207.
8.  Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, et al. 
Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-
up and monitoring therapeutic response in breast cancer patients. 
Anticancer Res. 1999; 19: 3511-5. 
9.  Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum 
miR-21 in breast cancer compared with CA153 and CEA. Chin J 
Cancer Res. 2013; 25: 743-8. 
10.  Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum 
tumor markers CEA and CA15-3 are prognostic parameters for 
different molecular subtypes of breast cancer. PLoS One. 2015; 10: 
e0133830. doi: 10.1371/journal.pone.0133830.
11.  Pissaia A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y. 
Significance of serum tumor markers carcinoembryonic antigen, CA 
19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation 
evaluation. Transplant Proc. 2009; 41: 682-4. 
12.  Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. 
MicroRNAs as novel biomarkers for breast cancer. J Oncol. 2009; 
2009: 950201. doi: 10.1155/2010/950201.
13.  Pan X, Wang ZX, Wang R. MicroRNA-21: A novel therapeutic target 
in human cancer. Cancer Biol Ther. 2010; 10: 1224–32. 
14.  Mar-Aguilar F, Mendoza-Ramírez JA, Malagón-Santiago I, Espino-
Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum 
circulating microRNA profiling for identification of potential breast 
cancer biomarkers. Dis Markers. 2013; 34: 163-9.
15.  Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, et al. Knockdown 
of miR-21 in human breast cancer cell lines inhibits proliferation, in 
164
Print ISSN: 2085-3297, Online ISSN: 2355-9179The Indonesian Biomedical Journal, Vol.12, No.2, June 2020, p.85-188
vitro migration and in vivotumor growth. Breast Cancer Res. 2011; 
13: R2. doi: 10.1186/bcr2803.
16.  Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, et al. High 
miR-21 expression in breast cancer associated with poor disease-
free survival in early stage disease and high TGF-β1. Breast Cancer 
Res Treat. 2009; 117: 131-40. 
17.  Fu SW, Chen L, Man YG. miRNA Biomarkers in Breast Cancer 
Detection and Management. J Cancer. 2011; 2: 116-22. 
18.  Suresh K, Chandrashekara S. Sample size estimation and power 
analysis for clinical research studies. J Hum Reprod Sci. 2012; 5: 
7-13. 
19.  Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, 
Fukutomi T. Long-term prognostic study of carcinoembryonic 
antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast 
cancer. Int J Clin Oncol. 2008; 13: 447. doi: 10.1007/s10147-008-
0773-3.
20.  Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges 
in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 
2015; 2015: 731479. doi: 10.1155/2015/731479.
21.  Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-
Agadjanyan EL, et al. Circulating microRNAs as stable blood-
based markers for cancer detection. Proc Natl Acad Sci USA. 2008; 
105: 10513-8. 
22.  Mirabelli P, Incoronato M. Usefulness of traditional serum biomarkers 
for management of breast cancer patients. Biomed Res Int.  2013; 
2013: 685641. doi: 10.1155/2013/685641.
23.  Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, 
et al. A novel source for miR-21 expression through the alternative 
polyadenylation of VMP1 gene transcripts. Nucleic Acids Res. 
2012; 40: 6821-33.
24.  Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer 
(Review). Biomed Reports. 2016; 5: 395-402. 
25.  Ma X, Choudhury SN, Hua X, Dai Z, Li Y. Interaction of the 
oncogenic miR-21 microRNA and the p53 tumor suppressor 
pathway. Carcinogenesis. 2013; 34: 1216-23. 
26.  Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets 
tumor suppressor genes in invasion and metastasis. Cell Res. 2008; 
18: 350-9. 
27.  Jiang LH, Ge MH, Hou XX, Cao J, Hu SS, Lu XX, et al. miR-21 
regulates tumor progression through the miR-21-PDCD4-Stat3 
pathway in human salivary adenoid cystic carcinoma. Lab Investig. 
2015; 95: 1398-408. 
28.  Ibrahim H, Fattah A, Mahmoud NH, Elzoghby DM, Matar MM, El-
shaer IMM. Clinical utility of circulating microRNA-21 in breast 
Cancer. Egypt J Hosp Med. 2018; 71: 2950-5. 
29.  Badr FM. Potential role of miR-21 in breast cancer diagnosis and 
therapy. Biotechnol Biomed Eng. 2016; 3: 1068.
30.  Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study 
of serum microRNA-21 as a diagnostic and prognostic biomarker in 
Egyptian breast cancer Patients. Mol Diagn Ther. 2015; 19: 179-90. 
31.  Han JG, Jiang YD, Zhang CH, Yang YM, Pang D, Song YN, et al. 
A novel panel of serum miR-21/miR-155/miR-365 as a potential 
diagnostic biomarker for breast cancer. Ann Surg Treat Res. 2017; 
92: 55-66.
8
